◆ NeutralIVA

Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

GlobeNewswire Inc.·
Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and disclosed preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The company has 209,007,475 shares outstanding with 218,082,368 total voting rights as of May 22, 2026.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence